Related Experiment Video
Updated: Aug 7, 2026

Single-molecule Imaging of Gene Regulation In vivo Using Cotranslational Activation by Cleavage (CoTrAC)
Published on: March 15, 2013
ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription
Masakatsu Eguchi1, Cu Nguyen, Sung Chan Lee
1Institute for Chemical Genomics, 600 Broadway, Suite 580, Seattle, WA 98122, USA.
Abstract:
Inherited and somatic mutations in the APC gene, a human tumor-suppressor, occur in a large percentage of colon cancers, leading to elevated levels of nuclear beta-Catenin, and to activation of TCF/beta-Catenin-responsive genes including cyclin D1 and c-myc. To identify small molecule antagonists of this pathway, we screened transformed colorectal cells with a secondary structure-templated chemical library, in search of compounds that attenuated a TCF/beta-Catenin-responsive reporter gene. From this library we selected ICG-001 (IC50=3 microM) as a lead compound. Design and synthesis of the chemical library and some preliminary biological evaluation is described.
Insights
Researchers identified ICG-001, a novel small molecule antagonist, that targets the TCF/beta-Catenin pathway. This pathway is frequently dysregulated in colon cancer, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutations in the APC gene are common in colon cancers, leading to increased nuclear beta-Catenin.
- Elevated beta-Catenin activates TCF/beta-Catenin-responsive genes like cyclin D1 and c-myc, promoting tumor growth.
Purpose of the Study:
- To identify small molecule antagonists targeting the TCF/beta-Catenin pathway.
- To find compounds that can attenuate TCF/beta-Catenin-responsive gene expression.
Main Methods:
- Screening of a secondary structure-templated chemical library against transformed colorectal cells.
- Utilizing a TCF/beta-Catenin-responsive reporter gene assay to identify active compounds.
- Design, synthesis, and preliminary biological evaluation of identified compounds.
Main Results:
- ICG-001 was identified as a lead compound with an IC50 of 3 microM.
- The study describes the design and synthesis of the chemical library used in the screen.
- Preliminary biological evaluation of ICG-001 was performed.
Conclusions:
- ICG-001 is a promising small molecule inhibitor of the TCF/beta-Catenin pathway.
- This compound represents a potential therapeutic lead for colon cancer treatment.
- The study highlights the utility of chemical library screening for drug discovery in oncology.
Related Concept Videos
TGF - β Signaling Pathway
Master Transcription Regulators
Hedgehog Signaling Pathway
Cis-regulatory Sequences
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Canonical Wnt Signaling Pathway

